ReNeuron Group (RENE)

Business description

ReNeuron is a UK biotech company developing allogeneic cell therapies: CTX neural stem cell products for stroke disability (Phase IIa) and critical limb ischaemia (Phase I); and human retinal progenitor cells for retinitis pigmentosa (Phase I/II).

Stock data

Market cap.£69.6m
Last close2.20p
High / Low (52 weeks)3.7p / 2.1p
Stock market listingLN
Forecast net cash (£m)49.4
Forecast gearing ratio (%)N/A
TeamHealthcare
SectorPharmaceutical & healthcare

Price performance

%1m3m12m
Actual(6.4)(17)(29.6)
Relative *(4)(17.2)(37.2)

* % Relative to local index

Other companies in sector Show

4SC aap Implantate
Aastrom Biosciences AB Science
Abcam Abivax SA
Ablynx Abzena
Acarix Achillion Pharmaceuticals
Acorda Therapeutics Actinium Pharmaceuticals
Active Biotech Acucela
Addex Therapeutics Adherium
Advanced Medical Solutions Aegerion Pharmaceuticals
Aeterna Zentaris AFT Pharmaceuticals
Agennix Akari Therapeutics
Alchemia Alexza Pharmaceuticals
Algeta Alimera Sciences
ALK Abello Alkermes
Allergy Therapeutics Alliance Pharma
Allium Medical Solutions Alnylam Pharmaceuticals
Amarantus BioScience Amarin
Amplifon AmpliPhi Biosciences
Angle Animalcare Group
Anteo Diagnostics Anthera Pharmaceuticals
Aratana Therapeutics Ardea Biosciences
Ardelyx Arena Pharmaceuticals
arGEN-X Argos Therapeutics
Ariad Pharmaceuticals Arix Bioscience
Ark Therapeutics Group ArQule
Array BioPharma Arrowhead Research Corporation
Ascendis Pharma Astex Pharmaceuticals
Athersys Atossa Genetics
Avacta Group Avalanche Biotechnologies
AVEO Pharmaceuticals Avita Medical
Balda Basilea Pharmaceutica
Bavarian Nordic BB Healthcare Trust
Bellus Health Benitec Biopharma
BioCryst Pharmaceuticals BioInvent
BioLight Life Sciences BioLineRx
Biondvax Pharmaceuticals Bionomics
Bionor Pharma Biota Holdings
Biotie Therapies Corp Biotron
Bluebird Bio Bone Therapeutics
BrainStorm Cell Therapeutics BTG
C4X Discovery Holdings Can-Fite BioPharma
Capstone Therapeutics Carmat
Cell Therapy Celldex Therapeutics
Cellectis Cellular Biomedicine Group
Celyad Cerulean Pharma
Circadian Technologies Clavis Pharma
Cleveland BioLabs Clinigen Group
Clinuvel co.don AG
Collplant Holdings Consort Medical
Corium International Crescendo
Crossject Curis
Cytori Therapeutics Cytos Biotechnology
CytRx Corporation DBV Technologies
Dechra Pharmaceuticals Delcath Systems
Deltex Medical Derma Sciences
DiaSorin Diaxonhit
e-Therapeutics Egalet Corporation
EKF Diagnostics Emergent BioSolutions
Endocyte Epigenomics
Erytech Pharma Esperion Therapeutics
Evotec Exact Sciences
Exelixis Factor Therapeutics
Formycon Forward Pharma
Fresenius SE & Co. KGaA Futura Medical
Galapagos Galmed Pharmaceuticals
Genedrive Genfit
Genkyotex Genmab
GeoVax GI Dynamics
Gilead Sciences GNI Group Ltd
GW Pharmaceuticals Halozyme Therapeutics
Horizon Discovery Hutchison China MediTech
Hybrigenics iCo Therapeutics
Idenix Immune Pharmaceuticals
Immunicum Immunodiagnostic Systems Holdings
Immunovia ImmuPharma
Imprimis Pharmaceuticals Imugene
Incyte Corporation Infinity Pharmaceuticals
Innate Pharma Insmed
Intec Pharma International Stem Cell Corporation
Invion Ion Beam Applications
Ipsogen Iridex
Ironwood Pharmaceuticals Islet Sciences
Ixico KaloBios Pharmaceuticals
Karolinska Development Keryx Biopharmaceuticals
Kiadis Pharma LCA-Vision
LeMaitre Vascular Lifeline Scientific
LifeWatch Ligand Pharmaceuticals
Lipocine Lombard Medical Technologies
MagForce Mast Therapeutics
Medcom Tech Medicago
MediciNova Medigene
Medivir Merrimack Pharmaceuticals
Merrion Pharmaceuticals Mesoblast
MethylGene Midatech Pharma
MISSION Therapeutics Molecular Partners
MolMed Mologen AG
Momenta Pharmaceuticals MorphoSys
Nanobiotix Nanosonics
Navidea Biopharmaceuticals Nektar Therapeutics
NeoStem Neovacs
NetScientific NeuroVive Pharmaceutical
Newron Pharmaceuticals Nexstim
NicOx NMC Health
NorDiag Nordion
NovaBay Pharmaceuticals Novacyt
Novogen NPS Pharmaceuticals
Nuevolution Ocata Therapeutics
Omega Diagnostics Group Omeros Corporation
OncoGenex Pharmaceuticals Oncolytics Biotech Inc
OncoMed Pharmaceuticals Onconova Therapeutics
Oncothyreon Onxeo
Onyx Pharmaceuticals Opexa Therapeutics
OPMEDIC Group Optos
Orexigen Therapeutics Orexo
Oryzon Genomics Ossur
OvaScience Oxford BioMedica
Pacific Edge Paion
Paladin Labs Patheon
PDL BioPharma Pharmacyclics
PharmaMar Pharmaxis
Pharming Group Photocure
Phylogica Pixium Vision
Pluristem Therapeutics Prescient Therapeutics
Prima BioMed Probiodrug
ProMetic Life Sciences Prosensa
Proteome Sciences PsiOxus
QRxPharma Quantum Genomics
Quantum Pharmaceuticals RedHill Biopharma
Regeneus Relmada Therapeutics
Resverlogix REVA Medical
ROVI Laboratorios Farmaceuticos RXi Pharmaceuticals
Sangamo BioSciences Sarepta Therapeutics
Sartorius Scancell
Selvita Shire
Silence Therapeutics Simavita
Sinclair Pharma Sirtex Medical
Skyepharma Smith & Nephew
Sobi Sosei Group Corporation
Source Bioscience SQI Diagnostics
Stallergenes StemCells
Stentys Stratec Biomedical
Sucampo Pharmaceuticals Sunesis Pharmaceuticals
Surgical Innovations Sygnis
SymBio Pharmaceuticals Synairgen
Synergy Health Synta Pharmaceuticals
TearLab Corp Tekmira
TESARO Theraclion
Threshold Pharmaceuticals ThromboGenics
TiGenix Tissue Regenix
Tissue Therapies Titan Pharmaceuticals
Tonix Pharmaceuticals Topotarget
Touchstone Innovations Transgene
Trillium Therapeutics Trimel Pharmaceuticals
TruScreen Ltd TxCell
UCB UDG Healthcare
uniQure NV Universal Biosensors
VBI Vaccines Vectura
Verastem Verisante Technology
Vernalis Verona Pharma
Vertex Pharmaceuticals Viralytics
ViroPharma Vivalis
Vivus VolitionRx
WaferGen Biosystems Wilex
Xbrane Biopharma Xencor
Zafgen Zealand Pharma
Ziopharm Oncology

Company news

ReNeuron update outlines ambitious plans for stroke and ophthalmology programmes

Fri, 21 Apr 2017 07:16:17 GMT

MySQUAR shares soar in afternoon deals

Fri, 21 Apr 2017 08:35:43 GMT

ReNeuron Group will hit "milestone" with results next year, says CEO

Tue, 06 Sep 2016 08:50:34 GMT

ReNeuron chief delighted with latest stroke data

Mon, 05 Dec 2016 08:25:11 GMT

ReNeuron makes a guest appearance on BBC2

Wed, 15 Feb 2017 08:07:01 GMT

Investment summary

ReNeuron is funded (£60m in cash at 30 Sept 2016) to undertake pivotal studies with two cell therapy-based programmes. This includes the CTX neural stem cell programme (recently announced positive Phase II study data in stroke disability and ongoing six-patient Phase I for critical limb ischaemia) and the hRPC (human retinal progenitor cells) programme for retinitis pigmentosa (a 15-patient Phase I/II trial is underway in the US). ReNeuron has also announced promising early pre-clinical data for its exosome nanomedicine platform in oncology, with the first clinical target being glioblastoma multiforme. The company is constructing a GMP cell manufacturing and research facility in South Wales (funded by a £7.8m Welsh government grant).

Last updated on 04/04/2017

Y/E Mar Revenue (£m) EBITDA (£m) PBT (£m) EPS (p) P/E (x) P/CF (x)
2015A 0.0 (10.3) (10.3) (0.50) N/A N/A
2016A 0.0 (13.6) (12.8) (0.44) N/A N/A
2017E 0.0 (19.9) (19.5) (0.58) N/A N/A
2018E 0.0 (31.5) (31.3) (0.93) N/A N/A

Last updated on 23/03/2017

Latest video

Executive Interview - ReNeuron

Industry outlook

Stroke is a high-risk indication, but ReNeuron is attempting to demonstrate a meaningful reduction in disability that would offer a compelling case for further development and/or partnering. Initial three month follow-up data from its Phase IIa stroke study was presented at H117 results, which were sufficiently strong for the Company to plan to progress to a pivotal controlled clinical study in 2017. The hRPC programme has Orphan (EU/US) and Fast Track (US) designation with a potentially pivotal Phase II/III study planned for 2018.

Last updated on 04/04/2017

Key management

John Berriman, Chairman
Olav Hellebø , CEO
Michael Hunt, CFO
John Sinden, Chief Scientific Officer

Company address

Pencoed Business Park
Pencoed
Bridgend
CF35 5HY
United Kingdom
+44 (0)1483 302560
View website